SecBot SecBot

TBPH

Theravance Biopharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. CA· CIK 0001583107 Biotech & Drug Discovery
No price
Market cap
$884.2M
Small cap
Median target
$17.00
range $17.00–19.00
Short interest
1.69M
≈3.3% of shares · +4.2%
Days to cover
4.5
at average volume
Insider net
$0
no open-market trades · since Sep 23
New fund stakes
0
Q3 2026 13F · 9 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 2 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/6

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Sep 23. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q3 2026: 0 added (0 new), 9 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate $0.200 → $0.200 over 90 days.

  • Short sellersSTEADY

    Short interest +4.2% to 1.69M shares. 4.5 days to cover, ≈3.3% of shares.

Who's buying

13F· Q3 2026
0
new positions
9
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jul 2026
Recent actions
DateFirmActionRating
Jul 7, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Jun 29, 2026Jones Trading
DOWNGRADE
DOWNGRADEHold
Jun 29, 2026BTIG
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$0
open-market buys or sells · since Sep 23
DateInsiderTypeValue
Sep 23, 2026🔒 Fresh data, subscribers only
Sep 23, 2026
OTHER
Sep 23, 2026
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
Sep 23, 2026
TO ISSUER124,414 sh
Sep 23, 2026
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
Sep 23, 2026
TO ISSUER89,062 sh
Sep 23, 2026
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
Sep 23, 2026
TO ISSUER150,000 sh
Sep 23, 2026
Grimaud Brett A.
SVP, GEN COUNSEL AND SECRETARY
Sep 23, 2026
TO ISSUER223,917 sh
Sep 23, 2026
Grimaud Brett A.
SVP, GEN COUNSEL AND SECRETARY
Sep 23, 2026
TO ISSUER107,812 sh
Sep 23, 2026
Miller Aine
SVP, DEV & HEAD OF IRE OFFICE
Sep 23, 2026
TO ISSUER93,108 sh
Sep 23, 2026
Grimaud Brett A.
SVP, GEN COUNSEL AND SECRETARY
Sep 23, 2026
TO ISSUER23,439 sh

Earnings setup

Estimates
$0.20
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.20$0.20–$0.20+0.0%$20.6M
Next Q-$0.08-$0.08–-$0.08+0.0%$22.1M
Current FY🔒 Fresh data, subscribers only
Next FY$1.27$0.80–$1.75+59.4%$84.8M

Short side

FINRA· Sep 15, 2026
1,686,673
shares short
+4.2%
vs prior settlement
4.5
days to cover
≈3.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 9, 2026 Earnings calendar
TBPH Q3 2026 Earnings Scheduled · 2026-11-09
Oct 5, 2026 SEC
Theravance Biopharma filed a Form 15 to terminate its SEC registration and suspend reporting obligations, effective…
15-12G · Impact 7/10
Sep 30, 2026 Inst.
MACKENZIE FINANCIAL CORP · EXIT
0 shares ($0.00)
Sep 30, 2026 Inst.
DIMENSIONAL FUND ADVISORS LP · EXIT
0 shares ($0.00)
Sep 25, 2026 SEC
Weiss Asset Management LP filed a Schedule 13D/A reporting that its stake in Theravance Biopharma was reduced to 0% as…
SC 13D/A · Impact 4/10
Sep 23, 2026 Insider
🔒 Fresh data, subscribers only
Sep 23, 2026 Insider
Farnum Rhonda disposed of 124,414 shares
SVP, COMM & MEDICAL AFFAIRS
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

12 filings · 4 bullish · 3 bearish · 1 mixed · 4 neutral
All TBPH filing & press-release reports (12)